Current and future therapy in muscular dystrophy; need for a common language between basic scientists and clinicians

Acta Myologica

Volumn 23, Issue 2, 2004, Pages

  Dubowitz, Victor ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Duchenne muscular dystrophy; Terminology

Indexed keywords

ADENOVIRUS VECTOR; ANABOLIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA GALACTOSIDASE; CORTICOSTEROID; CREATINE; DYSTROPHIN; NAKED DNA; PARVOVIRUS VECTOR; PREDNISOLONE; UTROPHIN;

CELL TRANSPLANTATION; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DUCHENNE MUSCULAR DYSTROPHY; EXPERIMENTAL ANIMAL; GENE THERAPY; HUMAN; KNEE ANKLE FOOT ORTHOSIS; MOBILIZATION; MYOBLAST; NOMENCLATURE; NONHUMAN; ORTHOSIS; PHENOTYPE; REVIEW; UPREGULATION;

ADRENAL CORTEX HORMONES; ANIMALS; DISEASE MODELS, ANIMAL; FORECASTING; GENE THERAPY; HUMANS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; ORTHOTIC DEVICES; TERMINOLOGY;

EID: 9344240818     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. nd edition. London: WB Saunders; 1995.
2. Manzur A, Kuntzer T, Pike MG, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy (Cochrane Review). The Cochrane Library. Chichester, UK: John Wiley and Sons Ltd; 2004.
3. Bushby K, Muntoni F, Urtizberea A, et al. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy: defining the gold standard of management. Naarden, The Netherlands, April 2-4th 2004. Neuromusc Disord 2004;14:526-34.
4. Partridge TA, Morgan JE, Coulton GR, et al Conversion of mdx myofibres from dystrophin-negative to positive by injection of normal myoblasts. Nature 1989;337:176-9.
5. Griggs RC, Karpati G. Myoblast Transfer Therapy. New York: Plenum Press; 1990.
6. Karpati G, Ajdukovic D, Arnold D, et al. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 1993;34:8-17.
7. Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003;301:487-92.
8. Thioudellet C, Blot S, Squiban P, et al. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: Rationale. Neuromusc Disord 2002;12:S49-51.
9. Romero NB, Benveniste O, Payan C, et al. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: Clinical protocol. Neuromusc Disord 2002;12:S45-S48.
10. Fardeau M. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part III: Ethical considerations. Neuromusc Disord 2002;12:S52-S54.
11. Aartsma-Rus A, Bremmer-Bout M, Janson AAM, et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromusc Disord 2002;12:S71-S77.
12. Perkins KJ, Davies KE. The role of utrophin in the potential therapy of Duchenne muscular dystrophy. Neuromusc Disord 2002;12:S78-S89.
13. Gregory LG, Waddington SN, Holder MV, et al. Highly efficient EIAV-mediated in utero gene transfer and expression in the major muscle groups affected by Duchenne muscular dystrophy. Gene Ther 2004; May 13 [Epub ahead of print].